Sai Life Sciences, Agility Life Sciences and Centrix Pharma Solutions today announced the launch of an Integrated CMC Partnership designed to provide innovator biopharma companies with end-to-end Chemistry, Manufacturing and Controls (CMC) services. The collaboration combines the CMC expertise of Sai Life Sciences in API development, Agility Life Sciences in formulation development and Centrix Pharma Solutions in drug product development and clinical manufacturing.

Through this partnership, customers will have access to integrated drug substance and drug product development, helping them move efficiently from pre-clinical studies to First-In-Human (FIH) clinical trials and beyond. 

By combining deep expertise across the CMC value chain, the Integrated CMC Partnership helps customers create and execute holistic development plans—translating molecular hits into new medicines. Key benefits include broad scientific expertise across multiple disciplines, supported by extensive laboratory and manufacturing facilities; end-to-end service coverage from synthetic route scouting to drug substance manufacturing, and from pre-formulation through to clinical trial material manufacturing; integrated planning across API and drug product development, reducing duplication, risks, costs, and timelines; agility and flexibility to respond proactively to emerging technical risks across functions; seamless coordination between technical teams, including proactive sample transfer and early API evaluation in the drug product process; and single point of contact from day one, ensuring alignment and accountability throughout project execution.

The result is a faster, more efficient and more collaborative pathway for innovators to advance their drug candidates with confidence.

Krishna Kanumuri, MD and CEO, Sai Life Sciences, said, "We are delighted to partner with Agility Life Sciences and Centrix Pharma in this truly integrated CMC offering. By bringing together our complementary strengths, we can deliver far greater value to innovators—helping them translate ideas into medicines with speed, quality and efficiency. This partnership reflects our shared commitment to supporting customers on their journey from discovery to the clinic, and ultimately, to patients.”

Adding to it, Dr Claire Thompson, CEO and Founder, Agility Life Sciences, said, “We are delighted to be entering this partnership with Sai and Centrix. Our combined expertise and energy will enable our clients’ molecules to be accelerated through key milestones, while reducing risk and cost.”

“What excites me the most about this partnership is the spirit of collaboration it represents. By bringing together talented teams across Sai, Agility and Centrix, we are creating a seamless environment where expertise flows freely, challenges are solved collectively, and clients benefit from true alignment. At its heart, this is about people working side by side to turn promising science into medicines that can change lives,” said Chris Davison, CEO, Centrix Pharma Solutions.